Mutated structural protein of a parvovirus
The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.
1. A method for vaccinating a mammal, the method comprising administering to the mammal a structural protein of an adeno-associated virus which comprises a first amino acid insertion of at least four amino acids into I-453 and a second amino acid insertion of at least four amino acids at a site different from I-453, wherein the first amino acid insertion and the second amino acid insertion are epitopes, and wherein the epitopes are identical within an epitope sequence of at least 4 amino acids.
2. The method of claim 1 , wherein the first amino acid insertion is directly C-terminal to amino acid G 453 in the sequence of AAV-2 or the corresponding amino acid of any other adeno-associated virus.
3. The method of claim 1 , wherein the first amino acid insertion and the second amino acid insertion are located on the surface of the capsid formed by the structural protein.
4. The method of claim 1 , wherein the structural protein with the first amino acid insertion and the second amino acid insertion is capable of particle formation.
5. The method of claim 1 , wherein the adeno-associated virus is selected from the group consisting of AAV-1, AAV-2, AAV-3b, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, and AAV-12.
6. The method of claim 1 , wherein the first amino acid insertion and the second amino acid insertion each have a length of 4 to about 30 amino acids.
7. The method of claim 1 , wherein the epitope of the first amino acid insertion and the second amino acid insertion is selected from the group consisting of a B-cell epitope, a tolerogen-derived epitope, and a cytotoxic T cell epitope.
8. The method of claim 1 , wherein the first amino acid insertion and the second amino acid insertion are a part of a protein selected from the group consisting of a tumor antigen, a misfolded protein, a serum protein, a membrane protein, a viral receptor, a TNF-family member and an interleukin.
9. The method of claim 7 , wherein the tolerogen-derived epitope is derived from a protein from the group consisting of CETP, CD20, acetylcholine receptors, IL13R, EGFR, IgE, Melan A, HMW MAA, CA125, Her2/NEU, CCR5, L1 cell adhesion molecule, VEGF, EGFR, CD20, TNF-α, IL-6, IL9, IL-13, IL-17, and β-amyloid.
10. The method of claim 9 , wherein the tolerogen-derived epitope is selected from the group consisting of VNLTWSRASG (SEQ ID NO: 50), EFCINHRGYWVCGD (SEQ ID NO:55), EDGQVMDVDLS (SEQ ID NO: 85), EKQRNGTLT (SEQ ID NO: 86), TYQCRVTHPHLPRALMR (SEQ ID NO: 87), RHSTTQPRKTKGSG (SEQ ID NO: 88), DSNPRGVSAYLSR (SEQ ID NO: 89), TITCLVVDLAPSK (SEQ ID NO: 90), KTKGSGFFVF (SEQ ID NO: 91), THPHLPRALMRS (SEQ ID NO: 92), GETYQCRVTHPHLPRALMRSTTK (SEQ ID NO: 93), LPRALMRS (SEQ ID NO: 94), INHRGYWV (SEQ ID NO: 95), CDAGSVRTNAPD (SEQ ID NO: 60), AKAVSNLTESRSESLQS (SEQ ID NO: 96), SLTGDEFKKVLET (SEQ ID NO: 97), REAVAYRFEED (SEQ ID NO: 98), INPEIITLDG (SEQ ID NO: 99), DISVTGAPVITATYL (SEQ ID NO: 100), DISVTGAPVITA (SEQ ID NO: 101), PKTVSNLTESSSESVQS (SEQ ID NO: 102), SLMGDEFKAVLET (SEQ ID NO: 103), QHSVAYTFEED (SEQ ID NO: 104), INPEIITRDG (SEQ ID NO: 105), DISLTGDPVITASYL (SEQ ID NO: 106), DISLTGDPVITA (SEQ ID NO: 107), DQSIDFEIDSA (SEQ ID NO: 108), KNVSEDLPLPTFSPTLLGDS (SEQ ID NO: 109), KNVSEDLPLPT (SEQ ID NO: 110), CDSGRVRTDAPD (SEQ ID NO: 111), FPEHLLVDFLQSLS (SEQ ID NO: 112), DAEFRHDSG (SEQ ID NO: 65), HYAAAQWDFGNTMCQL (SEQ ID NO: 113), YAAQWDFGNTMCQ (SEQ ID NO: 114), RSQKEGLHYT (SEQ ID NO: 115), SSRTPSDKPVAHVVANPQAE (SEQ ID NO: 116), SRTPSDKPVAHVVANP (SEQ ID NO: 117), SSRTPSDKP (SEQ ID NO: 118), NADGNVDYHMNSVP (SEQ ID NO: 119), DGNVDYHMNSV (SEQ ID NO: 120), RSFKEFLQSSLRALRQ (SEQ ID NO: 121); FKEFLQSSLRA (SEQ ID NO: 122), and QMWAPQWGPD (SEQ ID NO: 123).
11. The method of claim 1 , wherein the first amino acid insertion and the second amino acid insertion bring about an alteration in a chromatographic property of the structural protein and/or are each a tag useful for binding to a ligand.
12. The method of claim 1 , wherein the first amino acid insertion and the second amino acid insertion each have an N- and/or C-terminal linker.
13. The method of claim 12 , wherein the linker comprises at least one Cys N-terminal and at least one Cys C-terminal to the insertion.
14. The method of claim 1 , wherein the AAV structural protein comprises one or more further mutation(s) at a site different from I-453 independently selected from an internal deletion or a substitution, wherein the further mutation reduces the transducing activity of a particle formed from the AAV structural protein for a given target cell by at least 50%, wherein the further mutation is a mutation inactivating the HSPG binding site located in the proximity of 1-587, and wherein the further mutation is a deletion or substitution of R 585 and/or R 588 of AAV-2 or the corresponding amino acids of other AAV.
15. The method of claim 1 , wherein the AAV structural protein comprises one or more further mutation(s) at a site different from I-453 independently selected from a point mutation, an internal deletion, an N-terminal deletion, or a substitution, wherein the further mutation reduces the ability to induce a B-cell response against an AAV specific epitope and/or mimotope.
16. The method of claim 1 , wherein the mammal is a human.